4.7 Article

Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

Kobe C. Yuen et al.

NATURE MEDICINE (2020)

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Immunology

IL-6 as a keystone cytokine in health and disease

Christopher A. Hunter et al.

NATURE IMMUNOLOGY (2015)